Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

81.35 +2.02 (+2.55%)
Official Closing Price Updated: 7:00 PM EDT, Jun 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,254,140
Open 79.34
Bid (Size) 81.00 (1)
Ask (Size) 81.99 (1)
Prev. Close 79.33
Today's Range 79.33 - 81.88
52wk Range 73.31 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 3.98%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Pick in Pharmaceuticals
MERCK & CO. INC. (NYSE:MRK) is a value stock with strong profitability, a healthy balance sheet, and an attractive dividend. Trading below industry valuations, it may appeal to long-term investors. 
Via Chartmill

Performance

YTD
-18.0%
-18.0%
1 Month
+1.1%
+1.1%
3 Month
-14.1%
-14.1%
6 Month
-19.5%
-19.5%
1 Year
-38.1%
-38.1%

More News

Read More
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
Price Over Earnings Overview: Merck & Co
Via Benzinga
Unpacking the Latest Options Trading Trends in Merck & Co
Via Benzinga
How Do Investors Really Feel About Merck & Co?
Via Benzinga
Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials
Via Benzinga
Merck Announces Positive Data From Trials For Cholesterol Drug, But Retail Reaction Is Sluggish
Via Stocktwits
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Top S&P500 movers in Monday's pre-market session
Via Chartmill
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
From Merck & Co., Inc.
Via Business Wire
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Economy Stocks
Exposures Interest Rates US Equities
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
1 Value Stock to Target This Week and 2 to Question
Via StockStory
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover
Via Investor's Business Daily
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers
Via Benzinga
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
Via Investor's Business Daily
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
From Merck & Co., Inc.
Via Business Wire
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
From Merck & Co., Inc.
Via Business Wire
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of
Via StockStory

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 81.35
When was Merck & Co last traded?
The last trade of Merck & Co was at 06/10/25 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 205.93B
How many shares of Merck & Co are outstanding?
Merck & Co has 206B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.